Avantax Advisory Services’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.73M | Buy |
12,873
+199
| +2% | +$88.6K | 0.03% | 413 |
|
|
2025
Q1 | $6.14M | Buy |
12,674
+1,203
| +10% | +$583K | 0.04% | 353 |
|
|
2024
Q4 | $4.62M | Sell |
11,471
-1,037
| -8% | -$418K | 0.03% | 422 |
|
|
2024
Q3 | $5.82M | Buy |
12,508
+863
| +7% | +$401K | 0.04% | 350 |
|
|
2024
Q2 | $5.46M | Buy |
11,645
+5,307
| +84% | +$2.49M | 0.04% | 344 |
|
|
2024
Q1 | $2.65M | Buy |
6,338
+808
| +15% | +$338K | 0.02% | 465 |
|
|
2023
Q4 | $2.25M | Buy |
5,530
+580
| +12% | +$236K | 0.02% | 472 |
|
|
2023
Q3 | $1.72M | Buy |
4,950
+125
| +3% | +$43.5K | 0.02% | 505 |
|
|
2023
Q2 | $1.7M | Buy |
4,825
+1,748
| +57% | +$615K | 0.02% | 508 |
|
|
2023
Q1 | $969K | Buy |
3,077
+433
| +16% | +$136K | 0.01% | 677 |
|
|
2022
Q4 | $764K | Buy |
2,644
+1,477
| +127% | +$427K | 0.01% | 714 |
|
|
2022
Q3 | $338K | Sell |
1,167
-294
| -20% | -$85.2K | 0.01% | 945 |
|
|
2022
Q2 | $412K | Buy |
+1,461
| New | +$412K | 0.01% | 862 |
|
|
2020
Q4 | – | Sell |
-2,714
| Closed | -$737K | – | 1352 |
|
|
2020
Q3 | $737K | Sell |
2,714
-5,957
| -69% | -$1.62M | 0.01% | 647 |
|
|
2020
Q2 | $2.52M | Buy |
8,671
+5,849
| +207% | +$1.7M | 0.07% | 184 |
|
|
2020
Q1 | $671K | Buy |
2,822
+734
| +35% | +$175K | 0.02% | 371 |
|
|
2019
Q4 | $457K | Buy |
+2,088
| New | +$457K | 0.01% | 503 |
|